首页 > 最新文献

Current computer-aided drug design最新文献

英文 中文
In-silico Investigation of Ginseng Phytoconstituents as Novel Therapeutics Against MAO-A. 人参植物成分作为MAO-A新治疗药物的Silico研究。
Pub Date : 2024-01-01 DOI: 10.2174/0115734099266270230925090023
Diksha Choudhary, Rajwinder Kaur, Nidhi Rani, Thakur Gurjeet Singh, Bhupinder Kumar

Background: Ginseng (Panax ginseng) is a herb of medicinal and nutritional importance. Ginseng has been used since ancient times for the treatment of numerous ailments as it has many therapeutic properties. Several phytoconstituents are present in Panax ginseng that possess a variety of beneficial pharmacological properties.

Objective: To explore the potential of phytoconstituents of Panax ginseng in the treatment of depression, a molecular modeling technique was utilized targeting monoamine oxidase-A (MAO-A).

Methods: A total of sixty-one phytoconstituents of ginseng were drawn with the help of ChemBioDraw Ultra 12.0 software and PDBs for MAO-A enzyme were retrieved from the RCSB PDB database. The prepared ligands were screened for MAO-A properties using the software Molegro Virtual Docker (MVD 2010.4.1.0). All the prepared ligands were evaluated for drug-likeliness properties using Swiss ADME.

Results: Among the docking studies of 60 Ginseng phytochemicals including one standard, 15 phytoconstituents with the highest dock score and better binding interactions were selected further for absorption, distribution, metabolism and excretion (ADME) studies. Stachyose (-227.287, 17 interactions), Raffinose (-222.157, 14 interactions), and Ginsenoside Rg1 (-216.593, 10 interactions) were found to possess better interactions as compared to Clorgyline taken as a standard drug.

Conclusion: Stachyose was found to be the most potent inhibitor of MAO-A enzyme under investigation and can be a potential lead molecule for the development of newer phytochemical-based treatment of depression.

背景:人参是一种具有重要药用和营养价值的草本植物。人参自古以来就被用于治疗许多疾病,因为它具有许多治疗特性。人参中含有多种植物成分,具有多种有益的药理特性。目的:以单胺氧化酶a(MAOA)为靶点,采用分子模拟技术,探讨人参植物成分治疗抑郁症的潜力。方法:利用ChemBioDraw Ultra 12.0软件提取人参61种植物成分,并从RCSB PDB数据库中检索MAO-A酶的PDB。使用Molegro Virtual Docker软件(MVD 2010..4.1.0)对制备的配体进行MAO-A性质的筛选。使用瑞士ADME对所有制备的配位体的药物相似性进行评估。结果:在包括一个标准品在内的60种人参植物化学物质的对接研究中,进一步选择了15种具有最高对接得分和更好结合相互作用的植物成分进行吸收、分布、代谢和排泄(ADME)研究。与作为标准药物的Clorgyline相比,水苏糖(-227.287,17个相互作用)、拉菲糖(-222.157,14个相互作用。结论:水苏糖是目前研究中最有效的MAO-A酶抑制剂,可作为开发新型植物化学治疗抑郁症的潜在先导分子。
{"title":"<i>In-silico</i> Investigation of Ginseng Phytoconstituents as Novel Therapeutics Against MAO-A.","authors":"Diksha Choudhary, Rajwinder Kaur, Nidhi Rani, Thakur Gurjeet Singh, Bhupinder Kumar","doi":"10.2174/0115734099266270230925090023","DOIUrl":"10.2174/0115734099266270230925090023","url":null,"abstract":"<p><strong>Background: </strong>Ginseng (<i>Panax ginseng</i>) is a herb of medicinal and nutritional importance. Ginseng has been used since ancient times for the treatment of numerous ailments as it has many therapeutic properties. Several phytoconstituents are present in <i>Panax ginseng</i> that possess a variety of beneficial pharmacological properties.</p><p><strong>Objective: </strong>To explore the potential of phytoconstituents of <i>Panax ginseng</i> in the treatment of depression, a molecular modeling technique was utilized targeting monoamine oxidase-A (MAO-A).</p><p><strong>Methods: </strong>A total of sixty-one phytoconstituents of ginseng were drawn with the help of ChemBioDraw Ultra 12.0 software and PDBs for MAO-A enzyme were retrieved from the RCSB PDB database. The prepared ligands were screened for MAO-A properties using the software Molegro Virtual Docker (MVD 2010.4.1.0). All the prepared ligands were evaluated for drug-likeliness properties using Swiss ADME.</p><p><strong>Results: </strong>Among the docking studies of 60 Ginseng phytochemicals including one standard, 15 phytoconstituents with the highest dock score and better binding interactions were selected further for absorption, distribution, metabolism and excretion (ADME) studies. Stachyose (-227.287, 17 interactions), Raffinose (-222.157, 14 interactions), and Ginsenoside Rg1 (-216.593, 10 interactions) were found to possess better interactions as compared to Clorgyline taken as a standard drug.</p><p><strong>Conclusion: </strong>Stachyose was found to be the most potent inhibitor of MAO-A enzyme under investigation and can be a potential lead molecule for the development of newer phytochemical-based treatment of depression.</p>","PeriodicalId":93961,"journal":{"name":"Current computer-aided drug design","volume":" ","pages":"711-722"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41184573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the Molecular Mechanism of Niuxi-Mugua Formula in Treating Coronavirus Disease 2019 via Network Pharmacology, Computational Biology, and Surface Plasmon Resonance Verification. 通过网络药理学、计算生物学和表面等离子体共振验证,探索牛西木瓜方治疗2019冠状病毒病的分子机制。
Pub Date : 2024-01-01 DOI: 10.2174/0115734099272592231004170422
Wei Wang, Xu Cao, Yi-Nan Cao, Lian-Lian Liu, Shu-Ling Zhang, Wen-Ying Qi, Jia-Xin Zhang, Xian-Zhao Yang, Xiao-Ke Li, Xiao-Bin Zao, Yong-An Ye

Background: In China, Niuxi-Mugua formula (NMF) has been widely used to prevent and treat coronavirus disease 2019 (COVID-19). However, the mechanism of NMF for treating COVID-19 is not yet fully understood.

Objective: This study aimed to explore the potential mechanism of NMF for treating COVID- 19 by network pharmacology, computational biology, and surface plasmon resonance (SPR) verification.

Materials and methods: The NMF-compound-target network was constructed to screen the key compounds, and the Molecular Complex Detection (MCODE) tool was used to screen the preliminary key genes. The overlapped genes (OGEs) and the preliminary key genes were further analyzed by enrichment analysis. Then, the correlation analysis of immune signatures and the preliminary key genes was performed. Molecular docking and molecular dynamic (MD) simulation assays were applied to clarify the interactions between key compounds and key genes. Moreover, the SPR interaction experiment was used for further affinity kinetic verification.

Results: Lipid and atherosclerosis, TNF, IL-17, and NF-kappa B signaling pathways were the main pathways of NMF in the treatment of COVID-19. There was a positive correlation between almost the majority of immune signatures and all preliminary key genes. The key compounds and the key genes were screened out, and they were involved in the main pathways of NMF for treating COVID-19. Moreover, the binding affinities of most key compounds binding to key genes were good, and IL1B-Quercetin had the best binding stability. SPR analysis further demonstrated that IL1B-Quercetin showed good binding affinity.

Conclusion: Our findings provided theoretical grounds for NMF in the treatment of COVID-19.

背景:在我国,牛西mugaa方已被广泛用于预防和治疗2019冠状病毒病(新冠肺炎)。然而,NMF治疗新冠肺炎的机制尚不完全清楚。目的:本研究旨在通过网络药理学、计算生物学和表面等离子体共振(SPR)验证,探讨NMF治疗新冠肺炎的潜在机制。方法:构建NMF化合物靶向网络筛选关键化合物,利用分子复合物检测(MCODE)工具初步筛选关键基因。通过富集分析进一步分析了重叠基因和初步关键基因。然后,进行免疫特征与初步关键基因的相关性分析。应用分子对接和分子动力学(MD)模拟分析来阐明关键化合物和关键基因之间的相互作用。此外,SPR相互作用实验用于进一步的亲和动力学验证。结果:脂质和动脉粥样硬化、TNF、IL-17和NF-kappa B信号通路是NMF治疗新冠肺炎的主要途径。几乎大多数免疫特征与所有初步关键基因之间存在正相关。筛选出关键化合物和关键基因,它们参与了NMF治疗新冠肺炎的主要途径。此外,大多数关键化合物与关键基因的结合亲和力良好,IL1B槲皮素的结合稳定性最好。SPR分析进一步证明IL1B槲皮素具有良好的结合亲和力。结论:我们的研究结果为NMF治疗新冠肺炎提供了理论依据19。
{"title":"Exploring the Molecular Mechanism of Niuxi-Mugua Formula in Treating Coronavirus Disease 2019 <i>via</i> Network Pharmacology, Computational Biology, and Surface Plasmon Resonance Verification.","authors":"Wei Wang, Xu Cao, Yi-Nan Cao, Lian-Lian Liu, Shu-Ling Zhang, Wen-Ying Qi, Jia-Xin Zhang, Xian-Zhao Yang, Xiao-Ke Li, Xiao-Bin Zao, Yong-An Ye","doi":"10.2174/0115734099272592231004170422","DOIUrl":"10.2174/0115734099272592231004170422","url":null,"abstract":"<p><strong>Background: </strong>In China, Niuxi-Mugua formula (NMF) has been widely used to prevent and treat coronavirus disease 2019 (COVID-19). However, the mechanism of NMF for treating COVID-19 is not yet fully understood.</p><p><strong>Objective: </strong>This study aimed to explore the potential mechanism of NMF for treating COVID- 19 by network pharmacology, computational biology, and surface plasmon resonance (SPR) verification.</p><p><strong>Materials and methods: </strong>The NMF-compound-target network was constructed to screen the key compounds, and the Molecular Complex Detection (MCODE) tool was used to screen the preliminary key genes. The overlapped genes (OGEs) and the preliminary key genes were further analyzed by enrichment analysis. Then, the correlation analysis of immune signatures and the preliminary key genes was performed. Molecular docking and molecular dynamic (MD) simulation assays were applied to clarify the interactions between key compounds and key genes. Moreover, the SPR interaction experiment was used for further affinity kinetic verification.</p><p><strong>Results: </strong>Lipid and atherosclerosis, TNF, IL-17, and NF-kappa B signaling pathways were the main pathways of NMF in the treatment of COVID-19. There was a positive correlation between almost the majority of immune signatures and all preliminary key genes. The key compounds and the key genes were screened out, and they were involved in the main pathways of NMF for treating COVID-19. Moreover, the binding affinities of most key compounds binding to key genes were good, and IL1B-Quercetin had the best binding stability. SPR analysis further demonstrated that IL1B-Quercetin showed good binding affinity.</p><p><strong>Conclusion: </strong>Our findings provided theoretical grounds for NMF in the treatment of COVID-19.</p>","PeriodicalId":93961,"journal":{"name":"Current computer-aided drug design","volume":" ","pages":"1113-1129"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computer-aided Design of Wide-spectrum Coronavirus Helicase NSP13 Cage Inhibitors: A Molecular Modelling Approach. 广谱冠状病毒螺旋酶NSP13笼抑制剂的计算机辅助设计:一种分子建模方法。
Pub Date : 2024-01-01 DOI: 10.2174/0115734099247900231016055626
Vadim Shiryaev, Yuri Klimochkin

Background: The coronavirus helicase NSP13 plays a critical role in its life cycle. The found NSP13 inhibitors have been tested only in vitro but they definitely have the potential to become antiviral drugs. Thus, the search for NSP13 inhibitors is of great importance.

Objectives: The goal of the present work was to develop a general approach to the design of ligands of coronaviral NSP13 helicase and to propose on its basis potential inhibitors.

Methods: The structure of the NSP13 protein was refined by molecular dynamics and the cavity, responsible for RNA binding, was chosen as the inhibitor binding site. The potential inhibitor structures were identified by molecular docking and their binding was verified by molecular dynamics simulation.

Results: A number of potential NSP13 inhibitors were identified and the binding modes and probable mechanism of action of potential inhibitors was clarified.

Conclusion: Using the molecular dynamics and molecular docking techniques, we have refined the structure of the coronavirus NSP13 helicase, a number of potential inhibitors, containing cage fragment were proposed and their probable mechanism of action was clarified. The proposed approach is also suitable for the design of ligands interacting with other viral helicases.

背景:冠状病毒解旋酶NSP13在其生命周期中起着关键作用。发现的NSP13抑制剂仅在体外进行了测试,但它们肯定有潜力成为抗病毒药物。因此,寻找NSP13抑制剂具有重要意义。目的:本工作的目的是开发一种设计冠状病毒NSP13解旋酶配体的通用方法,并在此基础上提出潜在的抑制剂。方法:通过分子动力学方法对NSP13蛋白的结构进行纯化,并选择负责RNA结合的空腔作为抑制剂结合位点。通过分子对接鉴定了潜在的抑制剂结构,并通过分子动力学模拟验证了它们的结合。结果:鉴定出许多潜在的NSP13抑制剂,并阐明了潜在抑制剂的结合模式和可能的作用机制。结论:利用分子动力学和分子对接技术,我们已经完善了冠状病毒NSP13解旋酶的结构,提出了一些潜在的含有笼片段的抑制剂,并阐明了它们可能的作用机制。所提出的方法也适用于与其他病毒解旋酶相互作用的配体的设计。
{"title":"Computer-aided Design of Wide-spectrum Coronavirus Helicase NSP13 Cage Inhibitors: A Molecular Modelling Approach.","authors":"Vadim Shiryaev, Yuri Klimochkin","doi":"10.2174/0115734099247900231016055626","DOIUrl":"10.2174/0115734099247900231016055626","url":null,"abstract":"<p><strong>Background: </strong>The coronavirus helicase NSP13 plays a critical role in its life cycle. The found NSP13 inhibitors have been tested only in vitro but they definitely have the potential to become antiviral drugs. Thus, the search for NSP13 inhibitors is of great importance.</p><p><strong>Objectives: </strong>The goal of the present work was to develop a general approach to the design of ligands of coronaviral NSP13 helicase and to propose on its basis potential inhibitors.</p><p><strong>Methods: </strong>The structure of the NSP13 protein was refined by molecular dynamics and the cavity, responsible for RNA binding, was chosen as the inhibitor binding site. The potential inhibitor structures were identified by molecular docking and their binding was verified by molecular dynamics simulation.</p><p><strong>Results: </strong>A number of potential NSP13 inhibitors were identified and the binding modes and probable mechanism of action of potential inhibitors was clarified.</p><p><strong>Conclusion: </strong>Using the molecular dynamics and molecular docking techniques, we have refined the structure of the coronavirus NSP13 helicase, a number of potential inhibitors, containing cage fragment were proposed and their probable mechanism of action was clarified. The proposed approach is also suitable for the design of ligands interacting with other viral helicases.</p>","PeriodicalId":93961,"journal":{"name":"Current computer-aided drug design","volume":" ","pages":"1027-1041"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing the Extraction of Polyphenols from the Bark of Terminalia arjuna and an In-silico Investigation on its Activity in Colorectal Cancer. 从苍子皮中提取多酚类物质的工艺优化及其对癌症活性的计算机模拟研究。
Pub Date : 2024-01-01 DOI: 10.2174/0115734099264119230925054833
Tathagata Adhikary, Piyali Basak

Background: The interconnection between different fields of research has gained interest due to its cutting-edge perspectives in solving scientific problems. Terminalia arjuna is indigenously used in India for curing several diseases, and its pharmacological activities are being revisited in recent drug-repurposing research.

Objectives: Efficient ultrasound-assisted extraction of phytochemicals from the bark of Terminalia arjuna is highlighted in this study. Following the optimization of the extraction process, the crude hydroethanolic extract is subjected to phytochemical profiling and an in-silico investigation of its anti-cancer properties.

Materials and methods: A three-level four-factor Box-Behnken design is exploited to optimize four operational parameters, namely extraction time, ultrasonic power, ethanol concentration (as the extracting solvent) and solute (in g): solvent (in mL) ratio. At the optimum parametric condition, the crude extract is obtained, and its GC-MS analysis is carried out. An analysis of network pharmacology (by constructing and visualizing biological networks using Cytoscape) combined with molecular docking reveals the potential antineoplastic targets of the crude extract.

Results: The ANOVA table exhibits the significance, adequacy and reliability of the proposed second-order polynomial model with the R² value of 0.917 and adjusted R² of 0.865. Experimental results portray the significant antioxidant potential of the prepared extract in its crude form. The GC-MS analysis of the crude extract predicts the extracted phytochemicals, while the constructed biological networks highlight its multi-targeted activity in colorectal cancer.

Conclusion: The study identifies three phytochemicals viz. luteolin, β-sitosterol and arjunic acid as potent anti-cancer agents and can be extended with in-vitro and in-vivo experiments to validate the in-silico results, thus establishing lead phytochemicals in multi-targeted colorectal cancer therapies.

Backgtound:不同研究领域之间的相互联系因其在解决科学问题方面的前沿视角而引起了人们的兴趣。阿诸那在印度本土被用于治疗多种疾病,其药理活性在最近的药物再利用研究中被重新审视。目的:研究超声波辅助高效提取阿诸那树皮中的植物化学物质。在优化提取工艺后,对粗水乙醇提取物进行植物化学分析,并对其抗癌性能进行计算机模拟研究。方法:采用三级四因素Box-Behnken设计优化四个操作参数,即提取时间、超声功率、乙醇浓度(作为提取溶剂)和溶质(以g计)与溶剂(以mL计)的比例。在最佳参数条件下,得到了粗提物,并对其进行了GC-MS分析。网络药理学分析(通过使用Cytoscape构建和可视化生物网络)结合分子对接揭示了粗提取物的潜在抗肿瘤靶点。结果:方差分析表显示了所提出的二阶多项式模型的显著性、充分性和可靠性,R²值为0.917,调整后的R²为0.865。实验结果表明,粗提取物具有显著的抗氧化潜力。粗提取物的GC-MS分析预测了提取的植物化学物质,而构建的生物网络突出了其在癌症中的多靶向活性。结论:本研究确定木犀草素、β-谷甾醇和arjunic acid三种植物化学物质为有效的抗癌剂,并可通过体外和体内实验扩展以验证计算机模拟结果,从而在多靶向癌症治疗中建立副作用最小的先导植物化学物质。
{"title":"Optimizing the Extraction of Polyphenols from the Bark of <i>Terminalia arjuna</i> and an <i>In-silico</i> Investigation on its Activity in Colorectal Cancer.","authors":"Tathagata Adhikary, Piyali Basak","doi":"10.2174/0115734099264119230925054833","DOIUrl":"10.2174/0115734099264119230925054833","url":null,"abstract":"<p><strong>Background: </strong>The interconnection between different fields of research has gained interest due to its cutting-edge perspectives in solving scientific problems. <i>Terminalia arjuna</i> is indigenously used in India for curing several diseases, and its pharmacological activities are being revisited in recent drug-repurposing research.</p><p><strong>Objectives: </strong>Efficient ultrasound-assisted extraction of phytochemicals from the bark of <i>Terminalia arjuna</i> is highlighted in this study. Following the optimization of the extraction process, the crude hydroethanolic extract is subjected to phytochemical profiling and an <i>in-silico</i> investigation of its anti-cancer properties.</p><p><strong>Materials and methods: </strong>A three-level four-factor Box-Behnken design is exploited to optimize four operational parameters, namely extraction time, ultrasonic power, ethanol concentration (as the extracting solvent) and solute (in g): solvent (in mL) ratio. At the optimum parametric condition, the crude extract is obtained, and its GC-MS analysis is carried out. An analysis of network pharmacology (by constructing and visualizing biological networks using Cytoscape) combined with molecular docking reveals the potential antineoplastic targets of the crude extract.</p><p><strong>Results: </strong>The ANOVA table exhibits the significance, adequacy and reliability of the proposed second-order polynomial model with the R² value of 0.917 and adjusted R² of 0.865. Experimental results portray the significant antioxidant potential of the prepared extract in its crude form. The GC-MS analysis of the crude extract predicts the extracted phytochemicals, while the constructed biological networks highlight its multi-targeted activity in colorectal cancer.</p><p><strong>Conclusion: </strong>The study identifies three phytochemicals <i>viz</i>. luteolin, β-sitosterol and arjunic acid as potent anti-cancer agents and can be extended with <i>in-vitro</i> and <i>in-vivo</i> experiments to validate the <i>in-silico</i> results, thus establishing lead phytochemicals in multi-targeted colorectal cancer therapies.</p>","PeriodicalId":93961,"journal":{"name":"Current computer-aided drug design","volume":" ","pages":"653-665"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identify Diabetes-related Targets based on ForgeNet_GPC. 根据 ForgeNet_GPC 确定糖尿病相关目标。
Pub Date : 2024-01-01 DOI: 10.2174/0115734099258183230929173855
Bin Yang, Linlin Wang, Wenzheng Bao

Background: Research on potential therapeutic targets and new mechanisms of action can greatly improve the efficiency of new drug development.

Aims: Polygenic genetic diseases, such as diabetes, are caused by the interaction of multiple gene loci and environmental factors.

Objectives: In this study, a disease target identification algorithm based on protein recognition is proposed.

Materials and methods: In this method, the related and unrelated targets are collected from literature databases for treating diabetes. The transcribed proteins corresponding to each target are queried in order to construct a protein dataset. Six protein feature extraction algorithms (AAC, CKSAAGP, DDE, DPC, GAAP, and TPC) are utilized to obtain the feature vectors of each protein, which are merged into the full feature vectors.

Results: A novel classifier (forgeNet_GPC) based on forgeNet and Gaussian process classifier (GPC) is proposed to classify the proteins.

Conclusion: In forgeNet_GPC, forgeNet is utilized to select the important features, and GPC is utilized to solve the classification problem. The experimental results reveal that forgeNet_GPC performs better than 22 classifiers in terms of ROC-AUC, PR-AUC, MCC, Youden Index, and Kappa.

背景:研究潜在的治疗靶点和新的作用机制可以大大提高新药开发的效率。目的:糖尿病等多基因遗传病是由多个基因位点和环境因素相互作用引起的:本研究提出了一种基于蛋白质识别的疾病目标识别算法:方法:从治疗糖尿病的文献数据库中收集相关和不相关的靶点。方法:该方法从治疗糖尿病的文献数据库中收集相关和不相关的靶点,查询每个靶点对应的转录蛋白,从而构建蛋白质数据集。利用六种蛋白质特征提取算法(AAC、CKSAAGP、DDE、DPC、GAAP 和 TPC)获得每个蛋白质的特征向量,并将其合并为完整的特征向量:结果:提出了一种基于 forgeNet 和高斯过程分类器(GPC)的新型分类器(forgeNet_GPC)来对蛋白质进行分类:结论:在 forgeNet_GPC 中,forgeNet 被用来选择重要的特征,而 GPC 被用来解决分类问题。实验结果表明,forgeNet_GPC 在 ROC-AUC、PR-AUC、MCC、Youden Index 和 Kappa 方面的表现优于 22 种分类器。
{"title":"Identify Diabetes-related Targets based on ForgeNet_GPC.","authors":"Bin Yang, Linlin Wang, Wenzheng Bao","doi":"10.2174/0115734099258183230929173855","DOIUrl":"10.2174/0115734099258183230929173855","url":null,"abstract":"<p><strong>Background: </strong>Research on potential therapeutic targets and new mechanisms of action can greatly improve the efficiency of new drug development.</p><p><strong>Aims: </strong>Polygenic genetic diseases, such as diabetes, are caused by the interaction of multiple gene loci and environmental factors.</p><p><strong>Objectives: </strong>In this study, a disease target identification algorithm based on protein recognition is proposed.</p><p><strong>Materials and methods: </strong>In this method, the related and unrelated targets are collected from literature databases for treating diabetes. The transcribed proteins corresponding to each target are queried in order to construct a protein dataset. Six protein feature extraction algorithms (AAC, CKSAAGP, DDE, DPC, GAAP, and TPC) are utilized to obtain the feature vectors of each protein, which are merged into the full feature vectors.</p><p><strong>Results: </strong>A novel classifier (forgeNet_GPC) based on forgeNet and Gaussian process classifier (GPC) is proposed to classify the proteins.</p><p><strong>Conclusion: </strong>In forgeNet_GPC, forgeNet is utilized to select the important features, and GPC is utilized to solve the classification problem. The experimental results reveal that forgeNet_GPC performs better than 22 classifiers in terms of ROC-AUC, PR-AUC, MCC, Youden Index, and Kappa.</p>","PeriodicalId":93961,"journal":{"name":"Current computer-aided drug design","volume":" ","pages":"1042-1054"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139089708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis, and In-silico Studies of Indole-chalcone Derivatives Targeting Estrogen Receptor Alpha (ER-α) for Breast Cancer. 靶向癌症雌激素受体α(ER-α)的吲哚-查尔酮衍生物的合成和体内研究。
Pub Date : 2024-01-01 DOI: 10.2174/0115734099263650230926053750
Rahul Charudatta Choudhari, Kamalpreet Kaur, Agnidipta Das, Vikas Jaitak

Background: Breast cancer is the prominent reason of death in women worldwide, and the cases are increasing day by day. There are many FDA-approved drugs for treating breast cancer. Due to drug resistance, and problems in selectivity, there is a need to develop more effective agents with few side effects. Indole derivatives have demonstrated significant pharmacological potential as anti-breast cancer agents. Further, chalcone derivatives incorporating heterocyclic scaffolds play a significant role in medicine. Indole-chalcone-based compounds offer the potential for improved biological activity and enhanced drug-like properties. It prompted us to explore the synthesis of Indole-Chalcone derivatives targeting estrogen receptor alpha (ER-α) to discover potent anti-breast cancer agents.

Objectives: To synthesize indole-chalcone derivatives and study their binding interactions for ER-α protein by molecular docking for breast cancer treatment.

Methods: In this study, indole-chalcone derivatives have been synthesized using conventional heating. With the help of Schrodinger software, molecular interaction as well as ADME (Adsorption, Distribution, Metabolism, and Excretion) studies of the compounds were conducted.

Results: Among all the synthesized compounds, four compounds (1, 2, 3, and 4) showed better docking scores (-10.24 kcal/mol, -10.15 kcal/mol, -9.40 kcal/mol, -9.29 kcal/mol, respectively) than the standard tamoxifen (-8.43 kcal/mol).

Conclusion: From In-silico studies, we can conclude that four compounds from the synthesized series fit into the active site of ER-α. ADME properties of synthesized derivatives were found in the acceptable range. In the future, these compounds can be further explored for biological activity.

背景:癌症是全球女性死亡的主要原因,且发病率日益上升。有许多FDA批准的治疗乳腺癌症的药物。由于耐药性和选择性问题,需要开发出副作用较少的更有效的药物。吲哚衍生物已显示出作为抗乳腺癌症药物的显著药理潜力。此外,结合杂环支架的查尔酮衍生物在医学中发挥着重要作用。吲哚-查尔酮基化合物具有提高生物活性和增强类药物性质的潜力。这促使我们探索合成靶向雌激素受体α(ER-α)的吲哚-Chalcone衍生物,以发现有效的抗癌症药物。目的:合成吲哚醇酮衍生物,并通过分子对接研究其与ER-α蛋白的结合作用,为癌症治疗提供依据。方法:采用常规加热法合成吲哚查尔酮衍生物。在薛定谔软件的帮助下,对这些化合物进行了分子相互作用以及ADME(吸附、分布、代谢和排泄)研究。结果:在所有合成的化合物中,有4个化合物(1、2、3和4)的对接得分(分别为-10.24kcal/mol、-10.15kcal/mol,-9.40kcal/mol和-9.29kcal/mol)优于标准他莫昔芬(-8.43kcal/mol。合成的衍生物的ADME性质在可接受的范围内。在未来,这些化合物可以进一步探索其生物活性。
{"title":"Synthesis, and <i>In-silico</i> Studies of Indole-chalcone Derivatives Targeting Estrogen Receptor Alpha (ER-α) for Breast Cancer.","authors":"Rahul Charudatta Choudhari, Kamalpreet Kaur, Agnidipta Das, Vikas Jaitak","doi":"10.2174/0115734099263650230926053750","DOIUrl":"10.2174/0115734099263650230926053750","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the prominent reason of death in women worldwide, and the cases are increasing day by day. There are many FDA-approved drugs for treating breast cancer. Due to drug resistance, and problems in selectivity, there is a need to develop more effective agents with few side effects. Indole derivatives have demonstrated significant pharmacological potential as anti-breast cancer agents. Further, chalcone derivatives incorporating heterocyclic scaffolds play a significant role in medicine. Indole-chalcone-based compounds offer the potential for improved biological activity and enhanced drug-like properties. It prompted us to explore the synthesis of Indole-Chalcone derivatives targeting estrogen receptor alpha (ER-α) to discover potent anti-breast cancer agents.</p><p><strong>Objectives: </strong>To synthesize indole-chalcone derivatives and study their binding interactions for ER-α protein by molecular docking for breast cancer treatment.</p><p><strong>Methods: </strong>In this study, indole-chalcone derivatives have been synthesized using conventional heating. With the help of Schrodinger software, molecular interaction as well as ADME (Adsorption, Distribution, Metabolism, and Excretion) studies of the compounds were conducted.</p><p><strong>Results: </strong>Among all the synthesized compounds, four compounds (1, 2, 3, and 4) showed better docking scores (-10.24 kcal/mol, -10.15 kcal/mol, -9.40 kcal/mol, -9.29 kcal/mol, respectively) than the standard tamoxifen (-8.43 kcal/mol).</p><p><strong>Conclusion: </strong>From <i>In-silico</i> studies, we can conclude that four compounds from the synthesized series fit into the active site of ER-α. ADME properties of synthesized derivatives were found in the acceptable range. In the future, these compounds can be further explored for biological activity.</p>","PeriodicalId":93961,"journal":{"name":"Current computer-aided drug design","volume":" ","pages":"640-652"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54232864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Modelling of Resveratrol Derivatives with SIRT1 for the Stimulation of Deacetylase Activity. 具有SIRT1的白藜芦醇衍生物刺激脱乙酰酶活性的分子模型。
Pub Date : 2024-01-01 DOI: 10.2174/0115734099258321231003161602
Mozhdeh Zamani, Pooneh Mokarram, Mehdi Jamshidi, Morvarid Siri, Hadi Ghasemi

Background: Resveratrol is a polyphenol that is found in plants and has been proposed to have a potential therapeutic effect through the activation of SIRT1, which is a crucial member of the mammalian NAD+ -dependent deacetylases. However, how its activity is enhanced toward specific substrates by resveratrol derivatives has not been studied. This study aimed to evaluate the types of interaction of resveratrol and its derivatives with SIRT1 as the target protein, as well as to find out the best ligand with the strangest interaction with SIRT1.

Materials and methods: In this study, we employed the extensive molecular docking analysis using AutoDock Vina to comparatively evaluate the interactions of resveratrol derivatives (22 molecules from the ZINC database) as ligands with SIRT1 (PDB ID: 5BTR) as a receptor. The ChemDraw and Chem3D tools were used to prepare 3D structures of all ligands and energetically minimize them by the MM2 force field.

Results: The molecular docking and visualizations showed that conformational change in resveratrol derivatives significantly influenced the parameter for docking results. Several types of interactions, including conventional hydrogen bonds, carbon-hydrogen bonds, Pi-donor hydrogen bonds, and Pi-Alkyl, were found via docking analysis of resveratrol derivatives and SIRT1 receptors. The possible activation effect of resveratrol 4'-(6-galloylglucoside) with ZINC ID: ZINC230079516 with higher binding energy score (-46.8608 kJ/mol) to the catalytic domain (CD) of SIRT1 was achieved at the maximum value for SIRT1, as compared to resveratrol and its other derivatives.

Conclusion: Finally, resveratrol 4'-(6-galloylglucoside), as a derivative for resveratrol, has stably interacted with the CD of SIRT1 and might be a potential effective activator for SIRT1.

背景:白藜芦醇是一种在植物中发现的多酚,已被认为通过激活SIRT1具有潜在的治疗作用,SIRT1是哺乳动物NAD+依赖性脱乙酰酶的关键成员。然而,白藜芦醇衍生物如何增强其对特定底物的活性尚未得到研究。本研究旨在评估白藜芦醇及其衍生物与SIRT1作为靶蛋白的相互作用类型,并找出与SIRT1相互作用最奇怪的最佳配体,我们使用AutoDock-Vina进行了广泛的分子对接分析,以比较评估白藜芦醇衍生物(来自ZINC数据库的22个分子)作为配体与SIRT1(PDB ID:5BTR)作为受体的相互作用。ChemDraw和Chem3D工具用于制备所有配体的3D结构,并通过MM2力场使其能量最小化。结果:分子对接和可视化显示,白藜芦醇衍生物的构象变化显著影响对接结果的参数。通过对白藜芦醇衍生物和SIRT1受体的对接分析,发现了几种类型的相互作用,包括常规氢键、碳氢键、Pi供体氢键和Pi烷基。与白藜芦醇及其其他衍生物相比,具有ZINC ID:ZINC230079516的白藜芦醇4’-(6-加仑基葡糖苷)与SIRT1的催化结构域(CD)具有更高的结合能分数(-46.8608kJ/mol)的可能的活化作用在SIRT1的最大值处实现。结论:白藜芦醇4’-(6-没食子酰基葡糖苷)作为白藜芦醇的衍生物,与SIRT1的CD具有稳定的相互作用,可能是SIRT1的潜在有效激活剂。
{"title":"Molecular Modelling of Resveratrol Derivatives with SIRT1 for the Stimulation of Deacetylase Activity.","authors":"Mozhdeh Zamani, Pooneh Mokarram, Mehdi Jamshidi, Morvarid Siri, Hadi Ghasemi","doi":"10.2174/0115734099258321231003161602","DOIUrl":"10.2174/0115734099258321231003161602","url":null,"abstract":"<p><strong>Background: </strong>Resveratrol is a polyphenol that is found in plants and has been proposed to have a potential therapeutic effect through the activation of SIRT1, which is a crucial member of the mammalian NAD+ -dependent deacetylases. However, how its activity is enhanced toward specific substrates by resveratrol derivatives has not been studied. This study aimed to evaluate the types of interaction of resveratrol and its derivatives with SIRT1 as the target protein, as well as to find out the best ligand with the strangest interaction with SIRT1.</p><p><strong>Materials and methods: </strong>In this study, we employed the extensive molecular docking analysis using AutoDock Vina to comparatively evaluate the interactions of resveratrol derivatives (22 molecules from the ZINC database) as ligands with SIRT1 (PDB ID: 5BTR) as a receptor. The ChemDraw and Chem3D tools were used to prepare 3D structures of all ligands and energetically minimize them by the MM2 force field.</p><p><strong>Results: </strong>The molecular docking and visualizations showed that conformational change in resveratrol derivatives significantly influenced the parameter for docking results. Several types of interactions, including conventional hydrogen bonds, carbon-hydrogen bonds, Pi-donor hydrogen bonds, and Pi-Alkyl, were found via docking analysis of resveratrol derivatives and SIRT1 receptors. The possible activation effect of resveratrol 4'-(6-galloylglucoside) with ZINC ID: ZINC230079516 with higher binding energy score (-46.8608 kJ/mol) to the catalytic domain (CD) of SIRT1 was achieved at the maximum value for SIRT1, as compared to resveratrol and its other derivatives.</p><p><strong>Conclusion: </strong>Finally, resveratrol 4'-(6-galloylglucoside), as a derivative for resveratrol, has stably interacted with the CD of SIRT1 and might be a potential effective activator for SIRT1.</p>","PeriodicalId":93961,"journal":{"name":"Current computer-aided drug design","volume":" ","pages":"943-954"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Automation of Drug Discovery through Cutting-edge In-silico Research in Pharmaceuticals: Challenges and Future Scope. 通过尖端的药物计算机研究实现药物发现的自动化:挑战和未来范围。
Pub Date : 2024-01-01 DOI: 10.2174/0115734099260187230921073932
Smita Singh, Pranjal Kumar Singh, Kapil Sachan, Mukesh Kumar, Poonam Bhardwaj

The rapidity and high-throughput nature of in silico technologies make them advantageous for predicting the properties of a large array of substances. In silico approaches can be used for compounds intended for synthesis at the beginning of drug development when there is either no or very little compound available. In silico approaches can be used for impurities or degradation products. Quantifying drugs and related substances (RS) with pharmaceutical drug analysis (PDA) can also improve drug discovery (DD) by providing additional avenues to pursue. Potential future applications of PDA include combining it with other methods to make insilico predictions about drugs and RS. One possible outcome of this is a determination of the drug potential of nontoxic RS. ADME estimation, QSAR research, molecular docking, bioactivity prediction, and toxicity testing all involve impurity profiling. Before committing to DD, RS with minimal toxicity can be utilised in silico. The efficacy of molecular docking in getting a medication to market is still debated despite its refinement and improvement. Biomedical labs and pharmaceutical companies were hesitant to adopt molecular docking algorithms for drug screening despite their decades of development and improvement. Despite the widespread use of "force fields" to represent the energy exerted within and between molecules, it has been impossible to reliably predict or compute the binding affinities between proteins and potential binding medications.

硅技术的快速性和高通量特性使其有利于预测大量物质的性质。在药物开发之初,当没有或只有很少的化合物可用时,可以将硅方法用于合成化合物。硅方法可用于杂质或降解产物。通过药物分析(PDA)量化药物和相关物质(RS)也可以通过提供额外的途径来改善药物发现(DD)。PDA未来的潜在应用包括将其与其他方法相结合,对药物和RS进行原位预测。其中一个可能的结果是确定无毒RS的药物潜力。ADME估计、QSAR研究、分子对接、生物活性预测和毒性测试都涉及杂质分析。在进行DD之前,可以在计算机中使用毒性最小的RS。分子对接在将药物推向市场方面的功效仍然存在争议,尽管它得到了改进和改进。生物医学实验室和制药公司尽管经过几十年的发展和改进,但对采用分子对接算法进行药物筛选犹豫不决。尽管“力场”被广泛用于表示分子内部和分子之间施加的能量,但还不可能可靠地预测或计算蛋白质和潜在结合药物之间的结合亲和力。
{"title":"Automation of Drug Discovery through Cutting-edge <i>In-silico</i> Research in Pharmaceuticals: Challenges and Future Scope.","authors":"Smita Singh, Pranjal Kumar Singh, Kapil Sachan, Mukesh Kumar, Poonam Bhardwaj","doi":"10.2174/0115734099260187230921073932","DOIUrl":"10.2174/0115734099260187230921073932","url":null,"abstract":"<p><p>The rapidity and high-throughput nature of <i>in silico</i> technologies make them advantageous for predicting the properties of a large array of substances. <i>In silico</i> approaches can be used for compounds intended for synthesis at the beginning of drug development when there is either no or very little compound available. <i>In silico</i> approaches can be used for impurities or degradation products. Quantifying drugs and related substances (RS) with pharmaceutical drug analysis (PDA) can also improve drug discovery (DD) by providing additional avenues to pursue. Potential future applications of PDA include combining it with other methods to make insilico predictions about drugs and RS. One possible outcome of this is a determination of the drug potential of nontoxic RS. ADME estimation, QSAR research, molecular docking, bioactivity prediction, and toxicity testing all involve impurity profiling. Before committing to DD, RS with minimal toxicity can be utilised in silico. The efficacy of molecular docking in getting a medication to market is still debated despite its refinement and improvement. Biomedical labs and pharmaceutical companies were hesitant to adopt molecular docking algorithms for drug screening despite their decades of development and improvement. Despite the widespread use of \"force fields\" to represent the energy exerted within and between molecules, it has been impossible to reliably predict or compute the binding affinities between proteins and potential binding medications.</p>","PeriodicalId":93961,"journal":{"name":"Current computer-aided drug design","volume":" ","pages":"723-735"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41166183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In silico Exploration of a Novel ICMT Inhibitor with More Solubility than Cysmethynil against Membrane Localization of KRAS Mutant in Colorectal Cancer. 针对结直肠癌中 KRAS 突变体的膜定位,对溶解度高于 Cysmethynil 的新型 ICMT 抑制剂进行硅学探索。
Pub Date : 2024-01-01 DOI: 10.2174/0115734099264451231003172217
Mohammed Mouhcine, Youness Kadil, Ibtihal Segmani, Imane Rahmoune, Houda Filali

Background: ICMT (isoprenylcysteine carboxyl methyltransferase) is an enzyme that plays a key role in the post-translational modification of the K-Ras protein. The carboxyl methylation of this protein by ICMT is important for its proper localization and function. Cysmethynil (2-[5-(3-methylphenyl)-l-octyl-lH-indolo-3-yl] acetamide) causes K-Ras mislocalization and interrupts pathways that control cancer cell growth and division through inhibition of ICMT, but its poor water solubility makes it difficult and impractical for clinical use. This indicates that relatively high amounts of cysmethynil would be required to achieve an effective dose, which could result in significant adverse effects in patients.

Objective: The general objective of this work was to find virtually new compounds that present high solubility in water and are similar to the pharmacological activity of cysmethynil.

Materials and methods: Pharmacophore modeling, pharmacophore-based virtual screening, prediction of ADMET properties (absorption, distribution, metabolism, excretion, and toxicity), and water solubility were performed to recover a water-soluble molecule that shares the same chemical characteristics as cysmethynil using Discovery Studio v16.1.0 (DS16.1), SwissADME server, and pkCSM server.

Results: In this study, ten pharmacophore model hypotheses were generated by exploiting the characteristics of cysmethynil. The pharmacophore model validated by the set test method was used to screen the "Elite Library®" and "Synergy Library" databases of Asinex. Only 1533 compounds corresponding to all the characteristics of the pharmacophore were retained. Then, the aqueous solubility in water at 25°C of these 1533 compounds was predicted by the Cheng and Merz model. Among these 1533 compounds, two had the optimal water solubility. Finally, the ADMET properties and Log S water solubility by three models (ESOL, Ali, and SILICOS-IT) of the two compounds and cysmethynil were compared, resulting in compound 2 as a potential inhibitor of ICMT.

Conclusion: According to the results obtained, the identified compound presented a high solubility in water and could be similar to the pharmacological activity of cysmethynil.

背景:ICMT(异戊烯基半胱氨酸羧基甲基转移酶)是一种在 K-Ras 蛋白翻译后修饰中起关键作用的酶。ICMT 对这种蛋白质的羧基甲基化对其正常定位和功能非常重要。Cysmethynil(2-[5-(3-甲基苯基)-l-辛基-lH-吲哚-3-基]乙酰胺)可通过抑制 ICMT 导致 K-Ras 错位,并中断控制癌细胞生长和分裂的途径,但由于其水溶性较差,很难在临床上使用,也不切实际。这表明,要达到有效剂量,需要相对较高的西甲嘧啶用量,这可能会对患者造成严重的不良影响:这项工作的总体目标是找到在水中溶解度高且药理活性与西甲替尼相似的新化合物:方法:使用 Discovery Studio v16.1.0 (DS16.1)、SwissADME 服务器和 pkCSM 进行药效学建模、基于药效学的虚拟筛选、ADMET 特性(吸收、分布、代谢、排泄和毒性)预测和水溶性预测,以找到与 cysmethynil 具有相同化学特性的水溶性分子:本研究利用头孢羟氨苄的特性生成了十个药效模型假设。通过集合测试法验证的药效学模型被用于筛选 Asinex 的 "Elite Library®"和 "Synergy Library "数据库。只有 1533 个化合物符合药效库的所有特征。然后,利用 Cheng 和 Merz 模型预测了这 1533 个化合物在 25°C 水中的水溶性。在这 1533 个化合物中,有两个化合物具有最佳水溶性。最后,通过三种模型(ESOL、Ali 和 SILICOS-IT)比较了这两种化合物和 cysmethynil 的 ADMET 特性和 Log S 水溶性,结果发现化合物 2 是一种潜在的 ICMT 抑制剂:结论:根据所获得的结果,所发现的化合物在水中的溶解度很高,其药理活性可能与头孢羟氨苄相似。
{"title":"<i>In silico</i> Exploration of a Novel ICMT Inhibitor with More Solubility than Cysmethynil against Membrane Localization of KRAS Mutant in Colorectal Cancer.","authors":"Mohammed Mouhcine, Youness Kadil, Ibtihal Segmani, Imane Rahmoune, Houda Filali","doi":"10.2174/0115734099264451231003172217","DOIUrl":"10.2174/0115734099264451231003172217","url":null,"abstract":"<p><strong>Background: </strong>ICMT (isoprenylcysteine carboxyl methyltransferase) is an enzyme that plays a key role in the post-translational modification of the K-Ras protein. The carboxyl methylation of this protein by ICMT is important for its proper localization and function. Cysmethynil (2-[5-(3-methylphenyl)-l-octyl-lH-indolo-3-yl] acetamide) causes K-Ras mislocalization and interrupts pathways that control cancer cell growth and division through inhibition of ICMT, but its poor water solubility makes it difficult and impractical for clinical use. This indicates that relatively high amounts of cysmethynil would be required to achieve an effective dose, which could result in significant adverse effects in patients.</p><p><strong>Objective: </strong>The general objective of this work was to find virtually new compounds that present high solubility in water and are similar to the pharmacological activity of cysmethynil.</p><p><strong>Materials and methods: </strong>Pharmacophore modeling, pharmacophore-based virtual screening, prediction of ADMET properties (absorption, distribution, metabolism, excretion, and toxicity), and water solubility were performed to recover a water-soluble molecule that shares the same chemical characteristics as cysmethynil using Discovery Studio v16.1.0 (DS16.1), SwissADME server, and pkCSM server.</p><p><strong>Results: </strong>In this study, ten pharmacophore model hypotheses were generated by exploiting the characteristics of cysmethynil. The pharmacophore model validated by the set test method was used to screen the \"Elite Library<sup>®</sup>\" and \"Synergy Library\" databases of Asinex. Only 1533 compounds corresponding to all the characteristics of the pharmacophore were retained. Then, the aqueous solubility in water at 25°C of these 1533 compounds was predicted by the Cheng and Merz model. Among these 1533 compounds, two had the optimal water solubility. Finally, the ADMET properties and Log S water solubility by three models (ESOL, Ali, and SILICOS-IT) of the two compounds and cysmethynil were compared, resulting in compound 2 as a potential inhibitor of ICMT.</p><p><strong>Conclusion: </strong>According to the results obtained, the identified compound presented a high solubility in water and could be similar to the pharmacological activity of cysmethynil.</p>","PeriodicalId":93961,"journal":{"name":"Current computer-aided drug design","volume":" ","pages":"1055-1069"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141249064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clodronic Acid has Strong Inhibitory Interactions with the Urease Enzyme of Helicobacter pylori: Computer-aided Design and in vitro Confirmation. 氯膦酸对幽门螺杆菌脲酶有较强的抑制作用:计算机辅助设计及体外验证。
Pub Date : 2024-01-01 DOI: 10.2174/0115734099271837231026064439
Mohsen Karami Fath, Saeed Khalili, Masoud Mashhadi Akbar Boojar, Zahra Sadat Hashemi, Mahboubeh Zarei

Background: Helicobacter pylori (HP) infection could lead to various gastrointestinal diseases. Urease is the most important virulence factor of HP. It protects the bacterium against gastric acid.

Objective: Therefore, we aimed to design urease inhibitors as drugs against HP infection.

Methods: The DrugBank-approved library was assigned with 3D conformations and the structure of the urease was prepared. Using a re-docking strategy, the proper settings were determined for docking by PyRx and GOLD software. Virtual screening was performed to select the best inhibitory drugs based on binding affinity, FitnessScore, and binding orientation to critical amino acids of the active site. The best inhibitory drug was then evaluated by IC50 and the diameter of the zone of inhibition for bacterial growth.

Results: The structures of prepared drugs were screened against urease structure using the determined settings. Clodronic acid was determined to be the best-identified drug, due to higher PyRx binding energy, better GOLD FitnessScore, and interaction with critical amino acids of urease. In vitro results were also in line with the computational data. IC50 values of Clodronic acid and Acetohydroxamic Acid (AHA) were 29.78 ± 1.13 and 47.29 ± 2.06 μg/ml, respectively. Diameters of the zones of inhibition were 18 and 15 mm for Clodronic acid and AHA, respectively.

Conclusion: Clodronic acid has better HP urease inhibition potential than AHA. Given its approved status, the development of a repurposed drug based on Clodronic acid would require less time and cost. Further, in vivo studies would unveil the efficacy of Clodronic acid as a urease inhibitor.

背景:幽门螺杆菌(HP)感染可导致多种胃肠道疾病。脲酶是HP最重要的毒力因子。它可以保护细菌免受胃酸的侵害。目的:设计脲酶抑制剂作为抗HP感染的药物。方法:对药物银行批准的库进行三维构象分配,制备脲酶的结构。采用重新对接策略,通过PyRx和GOLD软件确定对接的适当设置。基于结合亲和力、FitnessScore和与活性位点关键氨基酸的结合取向,进行虚拟筛选以选择最佳抑制药物。然后用IC50和细菌生长抑制区直径评价最佳抑菌药物。结果:在所确定的设置条件下,对所制备药物的脲酶结构进行了筛选。氯膦酸由于具有较高的PyRx结合能、较好的GOLD FitnessScore以及与脲酶关键氨基酸的相互作用,被确定为最佳鉴定药物。体外实验结果也与计算数据一致。氯膦酸和乙酰羟肟酸(AHA)的IC50分别为29.78±1.13和47.29±2.06 μg/ml。氯膦酸和AHA的抑制区直径分别为18和15 mm。结论:氯膦酸对HP脲酶的抑制作用优于AHA。鉴于其被批准的地位,开发一种基于氯膦酸的重新用途药物将需要更少的时间和成本。此外,体内研究将揭示氯膦酸作为脲酶抑制剂的功效。
{"title":"Clodronic Acid has Strong Inhibitory Interactions with the Urease Enzyme of <i>Helicobacter pylori</i>: Computer-aided Design and <i>in vitro</i> Confirmation.","authors":"Mohsen Karami Fath, Saeed Khalili, Masoud Mashhadi Akbar Boojar, Zahra Sadat Hashemi, Mahboubeh Zarei","doi":"10.2174/0115734099271837231026064439","DOIUrl":"10.2174/0115734099271837231026064439","url":null,"abstract":"<p><strong>Background: </strong><i>Helicobacter pylori</i> (HP) infection could lead to various gastrointestinal diseases. Urease is the most important virulence factor of HP. It protects the bacterium against gastric acid.</p><p><strong>Objective: </strong>Therefore, we aimed to design urease inhibitors as drugs against HP infection.</p><p><strong>Methods: </strong>The DrugBank-approved library was assigned with 3D conformations and the structure of the urease was prepared. Using a re-docking strategy, the proper settings were determined for docking by PyRx and GOLD software. Virtual screening was performed to select the best inhibitory drugs based on binding affinity, FitnessScore, and binding orientation to critical amino acids of the active site. The best inhibitory drug was then evaluated by IC<sub>50</sub> and the diameter of the zone of inhibition for bacterial growth.</p><p><strong>Results: </strong>The structures of prepared drugs were screened against urease structure using the determined settings. Clodronic acid was determined to be the best-identified drug, due to higher PyRx binding energy, better GOLD FitnessScore, and interaction with critical amino acids of urease. <i>In vitro</i> results were also in line with the computational data. IC<sub>50</sub> values of Clodronic acid and Acetohydroxamic Acid (AHA) were 29.78 ± 1.13 and 47.29 ± 2.06 μg/ml, respectively. Diameters of the zones of inhibition were 18 and 15 mm for Clodronic acid and AHA, respectively.</p><p><strong>Conclusion: </strong>Clodronic acid has better HP urease inhibition potential than AHA. Given its approved status, the development of a repurposed drug based on Clodronic acid would require less time and cost. Further, <i>in vivo</i> studies would unveil the efficacy of Clodronic acid as a urease inhibitor.</p>","PeriodicalId":93961,"journal":{"name":"Current computer-aided drug design","volume":" ","pages":"1100-1112"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92158080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current computer-aided drug design
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1